Second Sight Receives FDA Approval to Begin Feasibility Study of Orion Cortical Visual Prosthesis System

September 1, 2017: By Joan McKenna

Second SightSecond Sight, maker of the Argus II retinal prosthesis system, announced Aug. 28 that it has received conditional approval from the US FDA to begin a feasibility study of its Orion Cortical Visual Prosthesis System.

The Sylmar, California, company may enroll up to five patients in total at two US sites: the University of California at Los Angeles and Baylor College of Medicine in Houston. The FDA has requested that the firm conduct additional device testing and address outstanding questions within 45 days.

Will McGuire, president and CEO of Second Sight, said in a statement: “The Orion team has met all major internal milestones this year, and we remain on track to achieve the company’s stated goal of implanting our first Orion patient before year end.”

Second Sight’s Orion is designed to convert images captured by a miniature video camera mounted on the patient’s glasses into a series of small electrical pulses. The Orion transmits these electrical pulses wirelessly to an array of electrodes implanted on the surface of the visual cortex. By bypassing the retina and optic nerve and directly stimulating the visual cortex, a cortical prosthesis system has the potential to restore useful vision to patients blinded due to many reasons, including glaucoma, diabetic retinopathy, or forms of cancer and trauma, the company said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

FDA Advisory Panel to Review Aerie’s Rhopressa in October

Johnson & Johnson Vision Acquires Online Contact Lens Business Sightbox

Novartis Returns OUS Rights for Jetrea to ThromboGenics

Eyevance Licenses Zerviate from Nicox for US Commercialization

Two Eye Projects Fail to Make Final Round for $100M Grant

Ophthotech Begins Phase IIa Trial for Zimura in Wet AMD

Graybug Vision Begins Phase I/II Trial for Candidate in Wet AMD

BioTime Receives $1.56 Million NIH Grant to Advance OpRegen for Dry AMD

FDA Approves Mvasi, a Biosimilar of Avastin Co-developed by Amgen, Allergan

Carl Zeiss Meditec Launches Zeiss Clarus 500 Ultra-Widefield Fundus Imaging System in US

Imprimis Appeals to Public Sentiment in Fiery Response to Allergan Lawsuit

Roche’s Lampalizumab Fails in Phase III Study in Geographic Atrophy

Aldeyra Reports Positive Phase IIa Results for Dry Eye Candidate ADX-102

US Denies Coherus’ Petitions Challenging AbbVie’s Patent for Humira

Ocular Therapeutix Names Michael Goldstein, MD, Chief Medical Officer

PhysIOL Agrees to Acquire Majority Stake in Italian Optikon

Rayner Creates US Subsidiary in New York

Inotek to Merge with Gene Therapy Startup Rocket

Allergan Agrees to $13.75 Million Deal with Tribe to Protect Restasis Patents

Ellex to Boost Production of iTrack Microcatheters to 50 Thousand a Year

Coming soon

2017 Retinal Pharmaceuticals and Biologics Report: A Global Market Analysis for 2016 to 2022